VIEW WEBSITE >>
1 known investors
Clyde Biosciences provides a human iPSC-derived cardiomyocyte platform called CellOPTIQ® that enables earlier detection of cardiovascular risk and cardiotoxicity assessment for pharmaceutical and biotech companies during drug development.
BiotechHealthtechMedical Devices